Outlook Therapeutics at RANZCO 52nd Annual Scientific Congress
Safety and efficacy results of ONS-5010, an ophthalmic bevacizumab from the NORSE TWO phase 3 study of monthly intravitreal ONS-5010 in subjects with wet AMD
Presenter: Lawrence Lee, MD, MBBS, FRANZCO, FRACS
Rapid Fire Session: Retina
Date and time: Saturday, February 26, 2022 from 9:45 PM – 10:15 PM ET (Sunday, February 27, 2022 from 13:45 PM – 14:15 PM AEDT)
For more information and to register for this event, please visit RANZCO 2022.